Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: A systematic review

Journal of the Canadian Urological Association

Volumn 4, Issue 3, 2010, Pages 201-208

  Canil, Christina ^a   Hotte, Sebastien ^b   Mayhew, Linda A ^c   Waldron, Tricia S ^c   Winquist, Eric ^d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953690363     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Canadian Cancer Society, National Cancer Institute of Canada. Canadian Cancel Statistics 2009. Toronto (Canada): National Cancer Institute of Canada; 2009.
2. Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology 1999;13:801-10.
3. Rabinovitch RA, Zelefsky Ml, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. I Clin Oncol 1994;12:206-12.
4. Amato R. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
5. Yagoda A, Abi-Rached B, Petiylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
6. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-intetferon as treatment for metastatic renal cell carcinoma. Br J Urol 1989;63:128-31.
7. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001;19:148-54.
8. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27:187-93.
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochtane Database Syst Rev 2005; Issue 2. D0I:10.1002/14651858.CD001425.pub2.
10. Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program [abstract]. Ann Oncol 2006;17:ix32.
11. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of the intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Soc Clin Oncol 2005;23:380s.
12. Negrier S, Perol D, Ravaud A, et al.; for the French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110:2468-77.
13. Parmar M, Torri V, Stewart L Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
14. Hernberg M, Pyrhönen S, Muhonen T. Regimens with or without interferon-a as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145-54.
15. Dexeus F, Logothetis C, Sella A, et al. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. J Clin Oncol 1989; 12:350-4.
16. Dutcher JP, Fine JP, KrigeIRL, et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 2003;20:271-81.
17. Foon K, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha 2B-interferon/gamma-inter-feron or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988;7:540-5.
18. Hancock B, Griffiths G, Ritchie A, et al. Updated results of the MRC randomised controlled trial of alpha interferon vs. MPA in patients with metastatic renal carcinoma [abstract], proc Am Soc Clin Oncol 2000;19:340a.
19. Medical Research Council Renal Cancer Collaborators. Interferon-a and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14-7.
20. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995;45:758-62.
21. Pyrhönen S, Salminen E, Lehtonen T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-67.
22. Steineck G, Strander H, Carbin B, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990;29:155-62.
23. Hartmann J, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999;19:1541-3.
24. Egger M, Dickerson K, Smith GD. Problems and limitations in conducting systematic reviews. In: Egger M, Smith GD, Altman D, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London: BMJ Publishing Group; 2001:43-68.